BioMimetic Stock Hits New 52-Week Low (BMTI)

NEW YORK ( TheStreet) -- BioMimetic Therapeutics (Nasdaq: BMTI) hit a new 52-week low Tuesday as it is currently trading at $4.03, below its previous 52-week low of $4.05 with 194,863 shares traded as of 12:25 p.m. ET. Average volume has been 645,300 shares over the past 30 days.

BioMimetic has a market cap of $123.1 million and is part of the health care sector and health services industry. Shares are down 61.1% year to date as of the close of trading on Monday.

BioMimetic Therapeutics, Inc., a biotechnology company, engages in the development and commercialization of regenerative protein therapeutic-device combination products for the treatment of musculoskeletal injuries and conditions affecting bones, tendons, ligaments, and cartilage.
  • Practice your BMTI trading strategies and win cash in our stock game.

TheStreet Ratings rates BioMimetic as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. You can view the full BioMimetic Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries